| INTRODUCTION
In 1994, the U.S. Public Health Service (PHS) released guidelines for preventing human immunodeficiency virus (HIV) transmission through organ transplantation. 1 These guidelines were updated in 2013 to reflect advances in laboratory HIV screening of organ donors, changes in understanding of risk factors, and further expanded to include hepatitis B and hepatitis C virus (HCV) transmission risks.
Specifically, the updated guidelines describe 11 criteria that result in a deceased organ donor being designated as 'increased risk' for viral bloodborne pathogen transmission. 1, 2 Three specific criteria were revised, men having sex with another man (MSM), non-medical intravenous drug use (IVDU), and sex in exchange for money (with a commercial sex worker [CSW]), to result in an 'increased-risk' donor (IRD) designation if behaviors occurred within the previous 12 months, rather than 5 years per the 1994 guideline. 1, 2 Another criterion, sex with a known HIV-infected partner (serodiscordant sex) in the previous 12 months resulted in an 'increased-risk' designation under both guidelines. 2 Increased-risk designation results in additional requirements for organ donor screening using nucleic acid testing (NAT), specific recipient informed consent, and enhanced post-transplant surveillance for detection of viral bloodborne pathogen transmission. 2 Use of IRD organs seldom results in transmission of HIV or HCV through solid organ transplantation, although such events have been recognized. [1] [2] [3] [4] [5] [6] [7] [8] [9] However, patient and provider apprehension regarding the perceived risks of HIV transmission from accepting organs from IRDs may result in under-utilization of potentially lifesaving organs. 10, 11 The apprehension regarding perceived risks of HCV transmission from accepting organs from an IRD because of a history of IVDU also may result in under-utilization of organs. 5, 6 The IRD designation results in a dichotomous (yes or no) classification based on whether the behavior occurred within the 12 months preceding organ donation.
In actuality the risk of HIV transmission from IRDs is likely to vary based on the type and timing of the increased-risk behavior. 12 In addition, the risk of HCV transmission from an IRD with a history of IVDU is likely based on the timing of the behavior. 6 In the setting of deceased organ donation, precise timing and type of behavior may be unknown to next-of-kin providing medical and behavioral risk information on a donor history questionnaire. The risk is further mitigated in the setting of highly sensitive and specific NAT, which has a window period of detection of 5-7 days from time of infection. 12 To improve organ utilization and better inform patients of actual risk of HIV and HCV transmission through use of IRD organs, a more quantitative assessment of risk based on type and timing of increased-risk behavior is required.
We developed a mathematical model to estimate the probability of undetected HIV infection in an IRD based on negative NAT and type of IRD behavior (including MSM, IVDU, serodiscordant sex, and sex with a CSW) from the time of increased-risk behavior relative to organ donation. The same model was used, with different parameters, to estimate the probability of undetected HCV infection in an IRD, specifically with history of IVDU, based on negative NAT and from the time of IVDU relative to organ donation. Estimates have been determined using data and modeling for per-act risk of transmission. This model may be helpful to providers and patients in making informed decisions regarding acceptance of an IRD organ. Implications for organ allocation are discussed.
| METHODS
To develop this mathematical model, two separate sets of methods were implemented in a sequential pattern. First, the published literature was reviewed to determine estimates related to the per-act HIV transmission rate for each increased-risk behavior entered in to the model (MSM, IVDU, sex with a CSW, and sex with a serodiscordant sex partner), performance characteristics of laboratory screening assays, and dynamics of acute HIV infection, specifically viral load (VL) growth. The revised PHS guidelines were expanded to include HCV owing to the risk of transmission because of IVDU and hemodialysis. Another review was completed to determine the estimated per-act HCV transmission rate of the increased risk behavior of IVDU, performance characteristics of laboratory screening assays, and dynamics of HCV infection, specifically VL growth. Per-act HCV transmission risks for hemodialysis were unavailable and were therefore not included in the analyses. Second, the estimates derived from published data were entered into a Monte Carlo statistical model to determine the probability of undetected HIV or HCV infection in an IRD based on negative NAT and type and timing of the behavior (including MSM, IVDU, serodiscordant sex, and sex with a CSW) in relation to the date of the NAT assay. The per-act IVDU risk of HCV transmission derived from the published data was also entered into a Monte Carlo statistical model to determine the probability of undetected HCV infection based on negative NAT and IVDU and timing of the IVDU behavior.
| Literature search and review methods
Review of the published literature consisted of a multistep process.
While the PHS guidelines describe 11 specific increased risk criteria for HIV infection, 9 of the 11 involve four specific behaviors: MSM, IVDU, sex with a CSW, and sex with a serodiscordant partner. These four behaviors were selected for this study because each of them is associated with the highest HIV risk according to the literature. 13 Papers related to the four selected increased risk behaviors were reviewed and studies were selected that estimated the per-act HIV transmission risk for the respective behavior along with associated 95% confidence intervals. Articles were reviewed and selected that estimated the per-act HCV transmission risk for IVDU along with the associated 95% confidence intervals. Articles describing mathematical models that generated transmission risk estimates, especially among populations engaging in increased-risk behaviors, were also selected.
The initial HIV PubMed search to determine published studies describing per-act transmission risk of the four selected increased-risk behaviors resulted in 8264 abstracts. Of these, 16 papers were identified that described randomized trials or observational, cohort-based studies where a per-act HIV transmission risk could be quantified for MSM, IVDU, sex with a CSW, or sex with a serodiscordant partner.
These 16 studies included 2 meta-analyses, which provided pooled estimates. Of these 16 studies, 5 were selected for inclusion into the model based on several factors (Table 1 5, 13, 15, 19, 21 ). The studies chosen had robust design, large cohorts, and long follow-up period. Therefore, the precision of the resulting estimates from these studies was robust and could be used in the model as the most accurate available estimation of per-act transmission risk for each increased-risk behavior. For this model, MSM behavior is defined as unprotected receptive anal intercourse because this confers the highest HIV transmission risk. 19, 20 Specifically, separate estimates were modeled based on ejaculation inside the rectum (MSM1) and risk regardless of ejaculation (MSM2). In the present study, per-act risk of HIV transmission, as described in a Thailand cohort among IVDU, was used. 13, 14 Serodiscordant couples are defined as a stable couple in which one partner is HIV positive. 17, 18 Table 1 includes the per-act risk estimates for each increased-risk behavior used to develop the model.
The HCV PubMed search to determine the published studies describing the per-act transmission risk for IVDU behavior resulted in 2166 abstracts. Of these, nine were identified that described randomized trials or observational, cohort-based studies where a per-act HCV transmission risk could be quantified for IVDU. The per-act risk used in the model was taken from Boelen et al. 5 The second PubMed search was conducted to understand the performance characteristics of HIV/HCV NAT screening assays in relation to the dynamics of acute HIV/HCV infection. The specific characteristics of the HIV/HCV NAT screening assays that were of interest were window period, sensitivity, specificity, and limit of detection. The viral dynamics of HIV/HCV were of interest in determining the VL from the day of infection to the day of seroconversion. After reviewing several studies of the performance of HIV/HCV NAT assays and the viral dynamics of HIV/HCV, these two cofactors for our model development were selected based on one mathematical modeling study. 22 This study was selected because it describes the risk of HIV/HCV transmission by NAT window-period blood donations.
| Statistical methods
Using estimates derived from the literature as described above inoculums were allowed to grow at an exponential rate with a normally distributed rate constant. The mean and standard deviation of the exponential growth rate constants for HIV and HCV are based on Weusten et al. 22 Finally, the threshold for detection by the NAT assays for HIV and HCV were also assumed to be lognormally distributed, 22 with means and variances consistent with the 95% high confidence bounds for the assay. Table 1 .
The resulting simulated values for Δt were recorded for all Monte
Carlo runs and fit to a Johnson Su distribution, 26 where the probability density function (pdf) for the distribution is (as a function of time from
where σ, δ, ξ, and γ are estimated parameters of the distribution.
Even for up to 10 000 Monte Carlo samples, the fit to the distribu- The fit of the Monte Carlo results to the Johnson Su distribution described above made the single-act risk probability calculations very computationally efficient. Because the per-act risk probabilities of transmitted HIV were relatively small (typically <2%, see Table 1 ), the risk probabilities for multiple risk acts behaved as if the probabilities for each risk act were working independently, so that the probabilities could be summed to a good approximation.
Computations of the risk for HIV exposures that occurred at uncertain times during a specified time interval were computed by numerically integrating (averaging) the risk probabilities over the interval, assuming the risk was uniformly distributed over that interval (ie, all times were equally likely for the risks to have occurred). Combinations of each type of risk, as shown in Figures 2 and 3 , were assumed to occur independently of one another.
| RESULTS
Results for a single risk-act of each type at known time of exposure are shown in Figure 1 . Of the six curves shown in Figure 1 , one applies to HCV infection (in bright red), the rest are for different types of HIV risk. These results are also presented in tabular form for certain time points in Table 2 . MSM1 risk for HIV infection was computed with the highest per-act risk defined as ejaculation inside rectum; MSM2 were computed with transmission risk regardless of ejaculation. The highest probability of undetected HIV infection for an individual risk behavior was for MSM1 at 1 day after engaging in the behavior. At 5 days after engaging in the behavior, the risk for MSM1 is 2.22%, which then decreases to 0.03% by 10 days, <0.01% by 14 days, and is negligible at 28 days. At the 6-month and 12-month marks, the probability of undetected HIV infection for MSM1 is effectively 0% with NAT screening. The probability of undetected HIV infection for MSM2 behavior was similar to MSM1 in the setting of NAT screening, although it decreases somewhat more slowly, as explained below. The risk of undetected HIV infection with negative NAT screening is lowest for sex with a CSW. At 1 and 10 days following exposure, the risks are 0.06% and 0.05%, respectively, but drop relatively more slowly compared to higher risk behaviors, for reasons explained below. Similar to the other behaviors studied, the risk rapidly declines after 7-10 days, and is near zero at 28 days. The dynamics are similar for HCV IVDU risk, except are faster than HIV owing to higher viral growth rates for HCV, which are somewhat offset by the higher threshold of detection for the NAT assay.
Confidence intervals and uncertainty bounds are built into the
Monte Carlo calculation, which can be seen if the results are presented slightly differently. For example, MSM1 risk carries a 2.85%
(1)
The figure shows risk of human immunodeficiency virus (HIV) or hepatitis C virus (HCV) being present despite negative nucleic acid testing vs time for different types of risk behavior, out to 20 days. MSM1 behavior is shown in blue, MSM2 in purple, sex with a serodiscordant partner (SeroD2) in magenta, HCV infection due to intravenous drug use (IVDU) in bright red, HIV infection due to IVDU in brown, and commercial sex work (Sex4$) in bright green. The high-risk act in each case is assumed to have occurred at day 0. MSM1, men having unprotected receptive intercourse with men with ejaculation inside the rectum; MSM2, men having unprotected intercourse with men regardless of ejaculation; serodiscordant, sex with a known HIV-infected partner Finally, Figure 4 shows the risk of HCV infection for IVDU as a function of exposure window, when the timing of the exposure within the window is uncertain (similar to Figure 3 for HIV, but with only one type of risk modeled).
| DISCUSSION
We developed a mathematical model to estimate the probabil- 6.66×10 reported. 11, 12, 28, 29 This under-utilization has been attributed to patient apprehension and provider reluctance owing to the perceived risk of viral bloodborne pathogen transmission. 11 The findings of the present study suggest that that the actual risk of HIV and HCV transmission is likely to be far lower than the perceived risk, particularly given the superior performance and low limit of detection of NAT assays used for screening organ donors, although this perception needs to be objectively measured. The decision to accept or reject an organ must be made after an individualized risk/benefit assessment by the patient and respective clinical team. However, the findings of this study can serve as a guide for informed consent discussions between potential recipients and transplant clinicians to more quantitatively convey risk
estimates.
The present analysis suggests that, although the risk of HIV is low in the setting of NAT, MSM behavior conveys the highest risk for undetected acute HIV infection. This observation is consistent with previous epidemiologic findings that suggest a high HIV incidence among MSM in the United States. 20, 30 Furthermore, MSM constitute the largest proportion of new HIV infections in the U.S. 31 In the U.S., the HIV prevalence among MSM has been reported to be substantially higher than among those with IVDU. 20, 32 The findings of this study are consistent with observations among other populations in the U.S. in that, at 1 and 5 days after exposure, the undetected HIV risk among
MSM was approximately twice the risk among donors with IVDU.
The findings of this study are subject to the following limitations.
First, the per-act transmissions rates of HIV for each increased-risk behavior were derived from some cohorts, specifically for serodiscordant sex, IVDU, and sex with a CSW, that were based in non-U.S. settings.
In some cases, these countries have different predominant HIV subtypes, prevalence, and incidence than the U.S. The impact on model findings are unknown, but could over-estimate the HIV transmission risk, specifically related to sex with a CSW. The per-act transmission rate for HCV was derived only from an IVDU cohort. There may be other risks for acquiring HCV; for example, hemodialysis and other F I G U R E 2 Surface plots show risk of human immunodeficiency virus (HIV) infection given negative nucleic acid testing as a function of days after two different risk behaviors. The plot z-axis shows risk in percentage points, the x-axis shows days since risk behavior type 1, and the y axis shows days since risk behavior type 2, out to 20 days at which the risks for both types become negligible (see Figure 1) . 
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